darunavir vs edoxaban
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of darunavir and edoxaban. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
dabigatran etexilate edoxaban ↑ dabigatran ↑ edoxaban Refer to the dabigatran etexilate or edoxaban prescribing information for recommendations regarding co-administration. The specific recommendations are based on indication, renal function, and effect of the co-administered P-gp inhibitors on the concentration of dabigatran or edoxaban. Clinical monitoring is recommended when a DOAC not affected by CYP3A4 but transported by P-gp, including dabigatran etexilate and edoxaban, is co-administered with darunavir /ritonavir.
Darunavir is a medicine used to treat HIV. It belongs to a class of drugs called protease inhibitors and must be taken with ritonavir.
Savaysa is a medicine that helps to prevent blood clots. It is used to lower the chance of stroke in people with an irregular heartbeat (atrial fibrillation) and to treat blood clots in the legs or lungs.
Darunavir is used to treat HIV-1 infection in adults and children 3 years and older. It must be taken with ritonavir and other HIV medicines. Darunavir helps to lower the amount of HIV in your body.
Savaysa is used to lower the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat. It is also used to treat blood clots in the deep veins of your legs (DVT) or in your lungs (PE). You will likely need to take another medicine to prevent blood clots for 5 to 10 days before starting Savaysa for DVT or PE.
Darunavir is a protease inhibitor. It works by blocking an enzyme called protease that HIV needs to make copies of itself. This helps to slow down the spread of HIV in your body.
Savaysa is a factor Xa inhibitor. This means it blocks a substance in your blood called factor Xa. By blocking factor Xa, Savaysa helps to prevent blood from clotting.
- • Diarrhea
- • Nausea
- • Rash
- • Headache
- • Abdominal pain
- • Bleeding
- • Anemia (low red blood cells)
- • Rash
- • Abnormal liver function tests
- Foetal Exposure During Pregnancy 1,150
- Drug Interaction 981
- Pain 889
- Emotional Distress 812
- Anxiety 811
No adverse event reports.
Darunavir can cause liver problems. Your doctor should check your liver before you start taking darunavir and during treatment. Tell your doctor right away if you have any signs of liver problems, such as yellowing of the skin or eyes.
Savaysa may not work as well to prevent strokes if you have atrial fibrillation and your kidneys are working very well (CrCl > 95 mL/min). If you stop taking Savaysa too soon, you have a higher risk of blood clots or stroke. If you get medicine injected into your spine while taking Savaysa, it could cause bleeding around your spine, which can lead to paralysis.
Tell your doctor if you are pregnant or plan to become pregnant. The recommended dose during pregnancy is 600 mg twice daily with ritonavir 100mg and food. Women with HIV should not breastfeed because HIV can be passed to the baby through breast milk.
Tell your doctor if you are pregnant or plan to become pregnant. Savaysa may increase the risk of bleeding in the fetus. Do not breastfeed while taking Savaysa.
Also Compare, Nearby Drugs
Compare edoxaban with
How to Read This darunavir vs edoxaban Comparison
darunavir is classified in the HIV Protease Inhibitor drug class, while edoxaban sits within the Direct Oral Anticoagulant (Factor Xa Inhibitor) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, darunavir has 4,643 submissions while edoxaban has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to darunavir stops a specific protein from moving edoxaban out of the body, which can increase the amount of medicine in your blood.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for darunavir or edoxaban.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.